England starts SMA heel-prick screening in October 2026

One of the smallest tests a newborn has could soon carry much more weight. England is set to begin screening babies for Spinal Muscular Atrophy, or SMA, through the heel-prick blood spot test from October 2026, with the expansion continuing through 2027 as part of a national evaluation. According to the Department of Health and Social Care, hundreds of thousands of babies will be covered by the widened screening offer. The hope is straightforward: spot SMA before symptoms appear, start treatment earlier, and give affected children the strongest possible chance of a healthier future. Ministers have also framed the move as part of reducing health inequalities, so that access does not depend on where a baby is born.

If you are wondering what SMA actually is, it helps to slow the jargon down. SMA is a rare genetic condition that damages motor neurons, the nerve cells that control muscle movement. As those cells are lost, muscles become weaker, which can affect how a baby sits, crawls, walks, breathes or swallows. **What this means:** SMA is serious not only because of what it does, but because it can move quickly. In the most severe cases, the loss of function can begin before families even know what they are looking at. That is why campaigners, clinicians and families have spent years arguing that time matters from day one.

The test itself is simple. A small blood sample is taken from a baby's heel shortly after birth, using the same newborn blood spot screening route already used in the NHS. Rather than creating a separate hospital appointment, the government plans to add SMA to an existing system. It is also worth being precise with the language. Screening is an early check, not the whole diagnostic process. In practice, it helps clinicians identify babies who may have SMA and need swift follow-up. For parents, that difference matters because it explains why a heel-prick test can change care so early in life.

Why does early timing matter so much here? Because with SMA, treatment before symptoms appear can significantly improve outcomes. NHS England has said the biggest difference comes when babies are identified early enough to reach specialist care before the condition has done more damage. That is the part of the story we should not rush past. A government announcement can make a screening change sound administrative, but for families it is deeply personal. Campaigner Jesy Nelson described the October start as a day of hope for future families. Giles Lomax, speaking for the SMA community, has made the same case in clinical terms: every day without treatment can mean irreversible loss of motor neurons.

The timetable is more concrete than many health policy announcements. The Department of Health and Social Care says the England-wide evaluation will begin in autumn 2026, with laboratories starting SMA screening from October 2026, three months earlier than first planned. The remaining screening laboratories are expected to join by October 2027, which is how the programme moves towards national coverage. **What this means for parents:** this is not an all-at-once switch flipped on a single day across every lab. It is a staged roll-out with a clear start date and a wider build through 2027. The department says it will seek investment to fund the expansion and has pointed to Scotland, where a similar programme is already in place with private sector backing.

There is another important layer here: evidence. Through the National Institute for Health and Care Research, the government has already committed £4.1 million to an evaluation led by scientists at the University of Oxford. The job of that study is to test, in a real NHS setting, whether adding SMA to newborn screening is feasible and effective. This matters because good screening policy should not rest on emotion alone, even when the human case is powerful. The Oxford-led work will help inform future recommendations from the UK National Screening Committee. In other words, England is not only widening access now; it is also building the evidence that could shape longer-term screening policy.

Health leaders and charities are treating the announcement as a landmark moment. Prof. Lucy Chappell of the NIHR has said the study is about turning early detection into rapid action. Michelle Kane of NHS England has said the expansion should both widen access for babies now and give independent experts the evidence they need later. Muscular Dystrophy UK has also described the move as a major step for families who have spent years pushing for change. You will often hear campaigners use the phrase postcode lottery in stories like this. It simply means a family's access to care can depend too heavily on where they live. That is the inequality campaigners are pushing against here, and it helps explain why nationwide screening matters so much.

The biggest lesson in this story is a simple one. When a condition moves quickly, a small head start can matter enormously. A heel-prick sample taken shortly after birth may sound routine, but for a baby with SMA it could mean earlier treatment, fewer lost chances and a very different beginning. **What this means for readers right now:** from October 2026, SMA screening is due to start in England through the newborn heel-prick programme, with the wider expansion continuing through 2027. This is both a health policy shift and a reminder of how change often happens in the NHS: families campaign, researchers test the evidence, and then a national system begins to move.